- Datum26.02.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Krystal Biotech Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Krystal Biotech Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-1,13 %
Intraday
-3,30 %
1 Woche
3,40 %
1 Monat
9,64 %
Seit Jahresbeginn
74,92 %
1 Jahr
252,04 %
3 Jahre
285,53 %
5 Jahre
Passender Service zu Krystal Biotech Inc.
Webinar zu Krystal Biotech Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)122,800-295,980
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Krystal Biotech Inc.
Keine Dividenden verfügbar
Termine von Krystal Biotech Inc.
- Feb17Krystal Biotech Inc.Q4 2025 Earnings Release
- Mai11Krystal Biotech Inc.Q1 2026 Earnings Release
- Aug10Krystal Biotech Inc.Q2 2026 Earnings Release
Beschreibung
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
